Pulmonary delivery of the Kv1.3-blocking peptide HsTX1[R14A] for the treatment of autoimmune diseases

Liang Jin, Qi (Tony) Zhou, Hak-Kim Chan, Ian C. Larson, Michael W. Pennington, Rodrigo A.V. Morales, Ben J. Boyd, Raymond S. Norton, Joseph A. Nicolazzo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

HsTX1[R14A] is a potent and selective Kv1.3 channel blocker peptide with the potential to treat autoimmune diseases. Given the typically poor oral bioavailability of peptides, we evaluated pulmonary administration of HsTX1[R14A] in rats as an alternative route for systemic delivery. Plasma concentrations of HsTX1[R14A] were measured by liquid chromatography coupled with tandem mass spectrometry in rats receiving intratracheal administration of HsTX1[R14A] in solution (1-4 mg/kg) or a mannitol-based powder (1 mg/kg) and compared with plasma concentrations after intravenous administration (2 mg/kg). HsTX1[R14A] stability in rat plasma and lung tissue was also determined. HsTX1[R14A] was more stable in plasma than in lung homogenate, with more than 90% of the HsTX1[R14A] remaining intact after 5 h, compared with 40.5% remaining in lung homogenate. The terminal elimination half-life, total clearance, and volume of distribution of HsTX1[R14A] after intravenous administration were 79.6 ± 6.5 min, 8.3 ± 0.6 mL/min/kg, and 949.8 ± 71.0 mL/kg, respectively (mean ± SD). After intratracheal administration, HsTX1[R14A] in solution and dry powder was absorbed to a similar degree, with absolute bioavailability values of 39.2 ± 5.2% and 44.5 ± 12.5%, respectively. This study demonstrated that pulmonary administration is a promising alternative for systemically delivering HsTX1[R14A] for treating autoimmune diseases.

Original languageEnglish
Pages (from-to)650-656
Number of pages7
JournalJournal of Pharmaceutical Sciences
Volume105
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Keywords

  • epithelial delivery
  • peptides
  • pharmacokinetics
  • pulmonary absorption
  • pulmonary drug delivery

Cite this

@article{fa06881a205047b0a77f9c9e946803fa,
title = "Pulmonary delivery of the Kv1.3-blocking peptide HsTX1[R14A] for the treatment of autoimmune diseases",
abstract = "HsTX1[R14A] is a potent and selective Kv1.3 channel blocker peptide with the potential to treat autoimmune diseases. Given the typically poor oral bioavailability of peptides, we evaluated pulmonary administration of HsTX1[R14A] in rats as an alternative route for systemic delivery. Plasma concentrations of HsTX1[R14A] were measured by liquid chromatography coupled with tandem mass spectrometry in rats receiving intratracheal administration of HsTX1[R14A] in solution (1-4 mg/kg) or a mannitol-based powder (1 mg/kg) and compared with plasma concentrations after intravenous administration (2 mg/kg). HsTX1[R14A] stability in rat plasma and lung tissue was also determined. HsTX1[R14A] was more stable in plasma than in lung homogenate, with more than 90{\%} of the HsTX1[R14A] remaining intact after 5 h, compared with 40.5{\%} remaining in lung homogenate. The terminal elimination half-life, total clearance, and volume of distribution of HsTX1[R14A] after intravenous administration were 79.6 ± 6.5 min, 8.3 ± 0.6 mL/min/kg, and 949.8 ± 71.0 mL/kg, respectively (mean ± SD). After intratracheal administration, HsTX1[R14A] in solution and dry powder was absorbed to a similar degree, with absolute bioavailability values of 39.2 ± 5.2{\%} and 44.5 ± 12.5{\%}, respectively. This study demonstrated that pulmonary administration is a promising alternative for systemically delivering HsTX1[R14A] for treating autoimmune diseases.",
keywords = "epithelial delivery, peptides, pharmacokinetics, pulmonary absorption, pulmonary drug delivery",
author = "Liang Jin and Zhou, {Qi (Tony)} and Hak-Kim Chan and Larson, {Ian C.} and Pennington, {Michael W.} and Morales, {Rodrigo A.V.} and Boyd, {Ben J.} and Norton, {Raymond S.} and Nicolazzo, {Joseph A.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.xphs.2015.10.025",
language = "English",
volume = "105",
pages = "650--656",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "Elsevier",
number = "2",

}

Pulmonary delivery of the Kv1.3-blocking peptide HsTX1[R14A] for the treatment of autoimmune diseases. / Jin, Liang; Zhou, Qi (Tony); Chan, Hak-Kim; Larson, Ian C.; Pennington, Michael W.; Morales, Rodrigo A.V.; Boyd, Ben J.; Norton, Raymond S.; Nicolazzo, Joseph A.

In: Journal of Pharmaceutical Sciences, Vol. 105, No. 2, 01.02.2016, p. 650-656.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pulmonary delivery of the Kv1.3-blocking peptide HsTX1[R14A] for the treatment of autoimmune diseases

AU - Jin, Liang

AU - Zhou, Qi (Tony)

AU - Chan, Hak-Kim

AU - Larson, Ian C.

AU - Pennington, Michael W.

AU - Morales, Rodrigo A.V.

AU - Boyd, Ben J.

AU - Norton, Raymond S.

AU - Nicolazzo, Joseph A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - HsTX1[R14A] is a potent and selective Kv1.3 channel blocker peptide with the potential to treat autoimmune diseases. Given the typically poor oral bioavailability of peptides, we evaluated pulmonary administration of HsTX1[R14A] in rats as an alternative route for systemic delivery. Plasma concentrations of HsTX1[R14A] were measured by liquid chromatography coupled with tandem mass spectrometry in rats receiving intratracheal administration of HsTX1[R14A] in solution (1-4 mg/kg) or a mannitol-based powder (1 mg/kg) and compared with plasma concentrations after intravenous administration (2 mg/kg). HsTX1[R14A] stability in rat plasma and lung tissue was also determined. HsTX1[R14A] was more stable in plasma than in lung homogenate, with more than 90% of the HsTX1[R14A] remaining intact after 5 h, compared with 40.5% remaining in lung homogenate. The terminal elimination half-life, total clearance, and volume of distribution of HsTX1[R14A] after intravenous administration were 79.6 ± 6.5 min, 8.3 ± 0.6 mL/min/kg, and 949.8 ± 71.0 mL/kg, respectively (mean ± SD). After intratracheal administration, HsTX1[R14A] in solution and dry powder was absorbed to a similar degree, with absolute bioavailability values of 39.2 ± 5.2% and 44.5 ± 12.5%, respectively. This study demonstrated that pulmonary administration is a promising alternative for systemically delivering HsTX1[R14A] for treating autoimmune diseases.

AB - HsTX1[R14A] is a potent and selective Kv1.3 channel blocker peptide with the potential to treat autoimmune diseases. Given the typically poor oral bioavailability of peptides, we evaluated pulmonary administration of HsTX1[R14A] in rats as an alternative route for systemic delivery. Plasma concentrations of HsTX1[R14A] were measured by liquid chromatography coupled with tandem mass spectrometry in rats receiving intratracheal administration of HsTX1[R14A] in solution (1-4 mg/kg) or a mannitol-based powder (1 mg/kg) and compared with plasma concentrations after intravenous administration (2 mg/kg). HsTX1[R14A] stability in rat plasma and lung tissue was also determined. HsTX1[R14A] was more stable in plasma than in lung homogenate, with more than 90% of the HsTX1[R14A] remaining intact after 5 h, compared with 40.5% remaining in lung homogenate. The terminal elimination half-life, total clearance, and volume of distribution of HsTX1[R14A] after intravenous administration were 79.6 ± 6.5 min, 8.3 ± 0.6 mL/min/kg, and 949.8 ± 71.0 mL/kg, respectively (mean ± SD). After intratracheal administration, HsTX1[R14A] in solution and dry powder was absorbed to a similar degree, with absolute bioavailability values of 39.2 ± 5.2% and 44.5 ± 12.5%, respectively. This study demonstrated that pulmonary administration is a promising alternative for systemically delivering HsTX1[R14A] for treating autoimmune diseases.

KW - epithelial delivery

KW - peptides

KW - pharmacokinetics

KW - pulmonary absorption

KW - pulmonary drug delivery

UR - http://www.scopus.com/inward/record.url?scp=84964465697&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2015.10.025

DO - 10.1016/j.xphs.2015.10.025

M3 - Article

VL - 105

SP - 650

EP - 656

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 2

ER -